Mechanism of PARP inhibitor resistance and potential overcoming strategies

PARP inhibitors (PARPi) are a kind of cancer therapy that targets poly (ADP-ribose) polymerase. PARPi is the first clinically approved drug to exert synthetic lethality by obstructing the DNA single-strand break repair process. Despite the significant therapeutic effect in patients with homologous r...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Xiaoyu, Li, Ping, Zhou, Qi, He, Ruyuan, Wang, Guannan, Zhu, Shiya, Bagheri, Amir, Kupfer, Gary, Pei, Huadong, Li, Juanjuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chongqing Medical University 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425807/
https://www.ncbi.nlm.nih.gov/pubmed/37588193
http://dx.doi.org/10.1016/j.gendis.2023.02.014
Descripción
Sumario:PARP inhibitors (PARPi) are a kind of cancer therapy that targets poly (ADP-ribose) polymerase. PARPi is the first clinically approved drug to exert synthetic lethality by obstructing the DNA single-strand break repair process. Despite the significant therapeutic effect in patients with homologous recombination (HR) repair deficiency, innate and acquired resistance to PARPi is a main challenge in the clinic. In this review, we mainly discussed the underlying mechanisms of PARPi resistance and summarized the promising solutions to overcome PARPi resistance, aiming at extending PARPi application and improving patient outcomes.

Ejemplares similares